ScholarWorks@Hanyang University: Cho, Soo Kyung

Detailed Information

Cho, Soo Kyung (조수경)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 류마티스내과

Tel 02-2290-9250
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Rheumatoid arthritis:32||rheumatoid arthritis:9||Prevalence:6||Arthritis:6||Epidemiology:6||Mortality:5||Osteoarthritis:5||Rheumatoid:5||Systemic lupus erythematosus:4||systemic lupus erythematosus:4||Rheumatoid Arthritis:4||Safety:4||rheumatoid:4||Osteoporosis:4||Incidence:4||Interstitial lung disease:4||Biologics:3||Biologic DMARDs:3||Ankylosing spondylitis:3||TNF inhibitor:3||osteoarthritis:3||Tumor necrosis factor inhibitor:3||Arthritis, Rheumatoid:3||arthritis:3||Latent tuberculosis:3||Comorbidity:3||Uric acid:2||psoriasis:2||Fatigue:2||rheumatic disease:2||Quality of life:2||DMARDs:2||Malignancy:2||RHEUMATOID ARTHRITIS:2||Claims data:2||Fractures:2||Rheumatic diseases:2||Discordance:2||Risk:2||validation:2||Risk Factors:2||Disease activity score:2||cohort study:2||Risk factors:2||Cohort studies:2||Immunosuppressive agents:2||Incidence rate:2||epidemiology:2||Biosimilar:2||genetic:2||Glucocorticoids:2||Drug therapy:2||Cancer:2||Corticosteroids:2||Janus kinase inhibitor:2||Therapeutics:2||Effectiveness:2||Knee:2||Korea:2||nonsteroidal:2||Korean Red Ginseng:2||Antirheumatic agents:2||Tuberculosis:2||polymorphism:2||Pregnancy:2||Etanercept:2||HLADRB1:1||HOUSEHOLD:1||Health Assessment Questionaire:1||Health Expenditure:1||Health assessment questionaire:1||Health assessment questionnairedisability index:1||Health services research:1||Healthrelated quality of life:1||Hemorrhage:1||Hindfoot:1||Households:1||Hyperuricemia:1||Hypouricemia:1||Idiopathic inflammatory myopathy:1||Idiopathic inflammatory myositis:1||Infection:1||Inflammatory Myopathy:1||Influencing factors:1||Interferongamma release tests:1||Intervention threshold:1||Isoniazid:1||Janus Kinase Inhibitor:1||Janus kinase inhibitors:1||Korean population:1||Latent Tuberculosis Infection:1||Leeds Satisfaction Questionnaire:1||Lung:1||Lupus erythematosus systemic:1||Lupus erythematosus, Systemic:1||Malignancies:1||Mapping:1||Medical Management:1||Medical care:1||Medical costs:1||Medical records:1||Medicare:1||Medication persistence:1||Midfoot:1||NSAIDs:1||Neoplasm:1||Nonsteroidal Antiinflammatory Drugs:1||Opioids:1||Oral ulcer:1||Organizing pneumonia:1||Osteoporosisa:1||Outcome assessment:1||Pain:1||Patient education:1||Patient global assessment:1||Patient reported outcome measures:1||Patient satisfaction:1||Patients reported outcomes:1||Physician global assessment:1||Polymyalgia Rheumatica:1||Polymyalgia rheumatica:1||Positron emission tomography computed tomography:1||Pregnancy outcome:1||Productivity loss:1||Proportion:1||PsO:1||QuantiFERONTB gold in tube test:1||RA:1||Rasch model:1||Registries:1||Remission:1||Rheumatoid arthritis (RA):1||Risk assessment:1||Risk factor:1||SEX:1||Self report:1||Seropositive rheumatoid arthritis:1||Severity of illness index:1||Sjogren&apos:1||Sjogren's syndrome:1||Sleep:1||Spinal Fractures:1||Spinal fractures:1||Standardised incidence ratio:1||Standardized incidence ratio:1||Systematic review:1||Systemic Lupus Erythematosus:1||TNF inhibitors:1||TNFalpha blockers:1||Targeted therapy:1||Trabecular bone score:1||Treatment:1||Treatment response:1||Trend:1||Tuberculin test:1||Tumor necrosis factor inhibitors:1||Tumor necrosis factoralpha:1||Tumor necrosis factoralpha inhibitor:1||Tumour necrosis factor inhibitor:1||Utility:1||Validation:1||Venous thromboembolism:1||Vertebral fracture:1||Vertebral fracture assessment (VFA):1||acetaminophen:1||active:1||acutephase protein:1||administrative claims data:1||antiinflammatory agents:1||antirheumatic agents:1||aspirin:1||autoimmune diseases:1||based algorithm:1||bioinformatics:1||biologic therapy:1||biological therapy:1||claims data:1||claims database:1||claims&:1||corticosteroid:1||crosscultural validation:1||dermatomyositis:1||diagnostic codes:1||diseasemodifying antirheumatic drugs (biologic):1||drug utilisation:1||effect:1||epistatic interaction:1||fracture:1||gout:1||hand:1||hematologic malignancy:1||histiocytic necrotizing lymphadenitis:1||hydroxychloroquine:1||immunosuppressive agents:1||incidence:1||interstitial lung disease:1||latent tuberculosis infection:1||lupus erythematosus:1||lymphadenopathy:1||medical utilization:1||medication:1||mortality:1||myositis:1||normal:1||opportunistic infections:1||osteonecrosis:1||patient health questionnaires:1||patientreported outcome:1||pharmacoepidemiology:1||polymyositis:1||primary Sjogren&apos:1||prospective study:1||psoriatic arthritis:1||quality of life:1||reproducibility of results:1||respiratory:1||s Syndrome:1||s syndrome:1||safety:1||seropositivity:1||skin:1||solid malignancy:1||statistics:1||systemic:1||therapeutics:1||tramadol:1||transcriptome:1||tuberculin skin test:1||tumor necrosis factor inhibitor:1||type I interferon:1||#8208:1||validation studies:1||2010 ACR/EULAR Classification Criteria:1||ADMINISTRATIVE CLAIMS:1||Abatacept:1||Adalimumab:1||Administrative claims healthcare:1||Algorithm:1||Algorithms:1||Amino acid:1||AntiTNF drugs:1||Antiinflammatory agents:1||Antiphospholipid antibody:1||Aphthous stomatitis:1||Arthralgia:1||Arthritis, rheumatoid:1||Atypical femoral fracture:1||Autoimmune diseases:1||Azathioprine:1||Back pain:1||Big data:1||Biologic DiseaseModifying Antirheumatic Drugs:1||Biologic diseasemodifying antirheumatic drugs:1||Bisphosphonates:1||Bone:1||Bone Mineral Density:1||Bone Scintigraphy:1||Bone density:1||COMPLEMENTARY AND ALTERNATIVE MEDICINE:1||COX Inhibitor:1||CRP:1||Cardiovascular disease:1||Chronic kidney disease:1||Chronic kidney failure:1||Clinical characteristics:1||Cohort:1||Comparative effectiveness research:1||Comparative effectiveness study:1||Copy number variations:1||Cyclosporine:1||DAS28:1||DEPRESSION:1||Depression:1||Diagnosis:1||Disease activity index:1||Diseasemodifying antirheumatic drugs:1||Drug efficacy:1||Drug retention rate:1||Drug utilization:1||EQ5D:1||ESR:1||Elderly:1||Etoricoxib:1||FRACTURE:1||Five dimensions:1||Fracture:1||Frequency:1||Functional disability:1||GLUCOCORTICOIDS:1||GWAS:1||Gastrointestinal diseases:1||Gender:1||Genetic polymorphism:1||Gout:1||Guideline:1||HAQ:1||HAQDI:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE